Search results
6 mar 2023 · In this Review, we describe the history of vaccines as treatments for prostate cancer and discuss vaccines that have been assessed in phase III clinical trials (Table 1) as well as other...
28 paź 2024 · Within the immunosuppressive tumor microenvironment of PCa, where regulatory T cells and myeloid-derived suppressor cells inhibit immune surveillance, DC vaccines aim to overcome these immune barriers by reactivating T-cell responses, thereby strengthening the immune attack on cancer cells.
In this Review, we describe the history of vaccines as treatments for prostate cancer and discuss vaccines that have been assessed in phase III clinical trials (Table 1) as well as other vaccines and combination approaches that have been tested or are currently being evaluated in clinical trials (Supplementary Table 1).
The vista for DNA vaccines in prostate cancer treatment is expansive. Future research should concentrate on refining vaccine design, understanding their intricate interaction with the immune system, and exploring synergies with other therapeutic strategies to amplify their efficacy.
7 sty 2014 · Prostate cancer is particularly well suited for immunotherapeutic approaches for three reasons. 1 First, early detection, along with the relatively indolent clinical course of prostate cancer, allows sufficient time to generate immune responses that may take weeks or months to mount.
In this Review, we describe the history of vaccines as treatments for prostate cancer and discuss vaccines that have been assessed in phase III clinical trials (Table 1) as well as other...
22 mar 2021 · Synthetic enhanced vaccines for prostate cancer antigens were shown to elicit antigen-specific immune responses in mice and the anti-tumor activity was evident in a prostate tumor challenge mouse model. These studies support further evaluation of the DNA tools for immunotherapy of prostate cancer and perhaps other cancers.
